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ABSTRACT
Introduction: Patients with either acromegaly 
or neuroendocrine tumors (NET) can be 
treated with somatostatin analogs to relieve 
symptoms and improve disease control. 
However, there is an absence of large clinical 
trials specifically designed to document 
the safety when increases in somatostatin 
analog dosing are needed in patients who 
do not achieve their treatment goals. 
To fully explore and communicate any 
potential risks, we conducted a literature 
review and present a summary of the studies 
documenting the safety and tolerability 
of dose optimization with somatostatin 
analogs in patients with acromegaly and NET. 
Methods: A literature search was undertaken 
to find clinical studies specifically reporting 
the effects of dose titration using the depot 
formulations of the somatostatin analogs, 
octreotide long-acting repeatable (LAR) or 
lanreotide, in patients with acromegaly and 
NET. Results: Publications that described 
the treatment and management of patients 
with acromegaly and NET were reviewed. The 
rationale for dose optimization, including 
high-dose treatment in patients who are 
inadequately controlled on conventional doses 
and the safety and tolerability of somatostatin 
analogs, is discussed. Conclusion: A review 
of published clinical studies demonstrates 
that dose optimization provides additional 
biochemical control in patients with 
acromegaly and NET who are inadequately 
controlled with conventional starting doses 
of octreotide LAR and lanreotide ATG. The 
benefits of dose optimization include improved 
efficacy without a significant change in the 
recorded adverse events and the tolerability 
of the treatment. Therefore, patient response 
to treatment should be routinely monitored 
and their somatostatin analog dose increased 
or decreased thereafter according to their 
individual response.
Keywords: acromegaly; dose optimization; 
lanreotide; neuroendocrine tumors; octreotide; 
safety; somatostatin analogs
826 Adv Ther (2011)  28(10):825-841.
INTRODUCTION
Until the development of the first somatostatin 
analog nearly three decades ago, patients 
who were diagnosed with acromegaly, a rare 
hormonal disorder caused by a pituitary 
adenoma, or neuroendocrine tumors (NET), 
malignant solid tumors that arise from 
neuroendocrine cells throughout the body, were 
limited in treatment to surgery or radiotherapy. 
Despite these treatment options, the negative 
impact on the patient’s quality of life from 
either disease remains considerable.1,2 If the 
progression of these diseases is recognized early 
and/or the patient is determined to be a suitable 
candidate, surgical resection of the tumor is the 
first-line, and most effective, treatment for either 
condition. However, it is common for both 
acromegaly and NET to remain undiagnosed 
until late in the progression of the disease when 
the suitability of the patient and the effectiveness 
of surgery may be reduced. Determining the 
method of treatment for acromegaly and NET is 
dependent on many variables. Although surgery 
is considered the first-line treatment, major 
progress in the management of both diseases 
has been made through the development and 
clinical use of highly specific and selective 
pharmacological agents. Currently, the options 
for the medical treatment of acromegaly include 
the use of dopamine agonists, somatostatin 
analogs, and growth hormone (GH) receptor 
antagonists.3 The medical treatment options for 
patients with NET include cytotoxic therapies 
with chemotherapy agents, inhibitors of 
cellular signaling pathways (tyrosine kinase, 
angiogenesis, or mammalian target of rapamycin 
[mTOR] inhibitors), or the use of somatostatin 
analogs to treat the symptoms associated with 
peptide-secreting NET.4 Although the choice 
of treatment may depend on the degree of 
differentiation and progression of the disease, 
the use of somatostatin analogs as a medical 
therapy to treat acromegaly and NET has become 
an important approach for controlling disease 
progression and the mainstay for the medical 
treatment of these diseases.
Outside of the US, the somatostatin analogs 
octreotide and lanreotide are indicated for 
the treatment of both acromegaly and the 
severe diarrhea/flushing episodes associated 
with metastatic carcinoid tumors. In the 
US, lanreotide is indicated only for the 
treatment of acromegaly. Both somatostatin 
analogs have been shown to reduce 
the symptoms and delay progression of 
these diseases.5-7 The therapeutic effect of 
somatostatin analogs occurs via the inhibition 
of a large number of endocrine secretory 
processes that are coupled to the binding/
activation of the G-protein coupled somatostatin 
receptors (sst) present on the surface of a variety 
of cell types. There are five sst isoforms (sst1-5) 
and, although the most prevalent sst found 
on the cell surface of pituitary adenomas 
and NET are sst2 and sst5, variable receptor 
expression may be a reason some patients 
do not respond fully to initial therapy 
(20 mg/28 days for octreotide long-acting 
repeatable [LAR] and 90 mg/28 days for 
lanreotide depot) and experience residual 
or breakthrough symptoms.8 In light of this 
need for additional therapy, recent consensus 
treatment guidelines for patients with 
acromegaly3,9 and NET10,11 have been updated 
to include titration of the somatostatin analog 
dose (ie, dose optimization). These guidelines 
recommend increasing the somatostatin 
analog dose in response to the patient’s need 
for additional symptom control or decreasing 
the dose if the patient has shown signs of 
improvement. In some patients, standard dosing 
is not sufficient to achieve symptom control 
and high-dose somatostatin analog therapy may 
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be considered in an effort to control the disease. 
Due to the rarity of these diseases, large clinical 
studies documenting the efficacy and safety 
of somatostatin analog therapy in hundreds 
of patients with acromegaly or NET do not 
exist. Consequently, numerous small studies 
are available for review; however, these studies 
were designed to demonstrate the efficacy of 
somatostatin analog treatment and only briefly 
report the general safety issues associated with 
dose optimization. To determine whether 
there is any additional safety risk associated 
with increasing the somatostatin analog dose, 
the results from these clinical studies were 
reviewed and any changes in adverse events 
following dose optimization were documented. 
The results of this review demonstrate that the 
practice of dose optimization, already known 
to improve the efficacy of somatostatin analog 
therapy, does not lead to a significant increase in 
adverse events. The presentation of these studies 
together will give clinicians the opportunity 
to review the clinical results from numerous 
patients, and may expand their understanding 
regarding the treatment of these diseases.
MATERIALS AND METHODS
A literature search of PubMed from January 1965 
to September 2010 was performed using the 
search terms “acromegaly” or “neuroendocrine 
tumor” and “dose optimization” or “dose 
titration.” Studies designed to evaluate the 
patient response to somatostatin analog therapy 
(octreotide LAR or lanreotide depot), including 
treatment at an increased dose or an increased 
frequency, were selected. Additionally, studies 
where dose optimization was undertaken, but 
was not the objective of the study, were included 
in the review. Related articles in non-peer-




The yearly incidence of acromegaly is roughly 
three new cases per million and the prevalence 
of acromegaly worldwide is estimated to be 
around 40-70 cases per million.12,13 However, the 
increasing number of patients being diagnosed 
with elevated insulin-like growth factor-1 (IGF-1) 
levels may indicate that acromegaly is under-
recognized clinically and could in fact be more 
common.14 Acromegaly is primarily caused by a 
GH-secreting pituitary adenoma that results in 
the hepatic over-production of IGF-1.15 Patients 
with untreated acromegaly experience a two- to 
threefold increase in mortality16,17 and a decrease 
in quality of life compared to healthy controls.18
Controlling GH and IGF-1 hypersecretion is the 
primary goal of treatment as reducing GH and 
IGF-1 levels in circulation has been shown to 
lower mortality rates to levels similar to that of 
the normal population.17,19 The characteristic 
signs and symptoms in patients with acromegaly 
(Figure 1) can range from physical signs of 
acral and musculoskeletal overgrowth to major 
systemic complications such as diabetes or 
impaired glucose tolerance, cardiovascular 
disease, or respiratory diseases that may ultimately 
contribute to the increase in mortality.15,20
Treatment Options for Patients with 
Acromegaly
The diagnosis and treatment of patients with 
acromegaly begins with biochemical confirmation 
of increased GH and IGF-1 levels followed 
by surgical or medical treatment (Figure 2). 
Complete biochemical control is defined as serum 
GH <1 μg/L without oral glucose load and 
normalization of serum IGF-1 levels compared 
to age- and sex-matched controls.3,21 The goals 
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Figure 1. Signs and symptoms of acromegaly.
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of treatment are to attain biochemical control, 
control tumor growth, and prevent recurrence.15,22
For most patients, transsphenoidal adenomectomy 
(TSA) by a dedicated and experienced pituitary 
neurosurgeon is the first-line treatment option.23-26
In addition to surgical treatment, the American 
Association of Clinical Endocrinologists (AACE) 
reviews the pharmacological options for the 
treatment of acromegaly and recommends medical 
therapy for the treatment of persistent acromegaly 
and for treatment of patients who are not 
candidates for surgery.3,21 The options for medical 
therapy include: somatostatin analogs, dopamine-
receptor agonists, and GH-receptor analogs. 
Somatostatin analogs are the first choice21 and 
should be considered before undergoing surgery 
to improve severe co-morbidities that prevent 
or could complicate immediate surgery,27 as a 
first-line therapy when there is a low probability 
of surgical cure,28,29 after surgery has failed to 
achieve biochemical control, or in combination 
with radiation therapy.3 GH-receptor analogs 
(ie, pegvisomant) are only effective in lowering 
IGF-1 levels and are typically used when other 
treatments have proven to be ineffective. The 
limited clinical data report that dopamine receptor 
agonists (ie, cabergoline and bromocriptine) are 
far less effective than either somatostatin analogs 
or GH-receptor blockers and are typically used in 
combination with somatostatin analog therapy.
Somatostatin Analog Therapy in Patients 
with Acromegaly 
Somatostatin analogs have a well-established 
efficacy profile and patients do not typically 
discontinue treatment due to adverse events. 
A recent meta-analysis reviewed the efficacy 
results of more than 600 patients (regardless 
of somatostatin analog responsiveness).30 
The analysis determined that treatment with 
long-acting somatostatin analogs as secondary 
therapy improved biochemical control. 
Specifically, the reported proportion of patients 
in whom there was a reduction in GH level 
(<2.5 μg/L) and normalization of IGF-1 was 
57% and 67%, respectively, following octreotide 
LAR therapy, and 48% and 47%, respectively, 
following therapy with lanreotide depot.30
However, efficacy results vary greatly among 
studies and are dependent on the patient 
population, the definition of response, and the 
outcome of previous treatments. The safety of 
octreotide LAR in the treatment of acromegaly 
was initially evaluated in three phase 3 studies 
in 261 patients, including 209 exposed for 
48 weeks and 96 exposed for greater than 
108 weeks. Most patients received a starting 
dose of 20 mg every 4 weeks intramuscularly. 
The dose was titrated based on efficacy and 
tolerability to a final dose of 10-60 mg every 
4 weeks. Adverse events occurring in >10% of 
patients were mostly gastrointestinal (diarrhea, 
abdominal pain, and flatulence) and a few 
patients discontinued therapy because of these 
symptoms. Other adverse events included 
gall-bladder abnormalities (gallstones, sludge 
without stones, and biliary duct dilation), 
headache/nausea, alopecia, injection-site pain, 
hypertension, and fatigue. Similarly, the safety 
of lanreotide depot was evaluated in seven 
studies that included a total of 416 patients. 
The most commonly reported adverse reactions 
reported by >5% of patients were gastrointestinal 
disorders (diarrhea, abdominal pain, nausea, 
constipation, flatulence, vomiting, and loose 
stools), cholelithiasis and gall-bladder sludge, 
and injection-site reactions.31 Both somatostatin 
and somatostatin analogs inhibit the secretion 
of insulin and glucagon. Therefore, patients 
may experience hypoglycemia or hyperglycemia 
and blood glucose levels should be monitored 
in patients with co-morbid conditions, such as 
diabetes mellitus, when treatment is initiated 
830 Adv Ther (2011)  28(10):825-841.
Clinical features of acromegaly
Figure 2. The diagnosis and treatment of acromegaly. CT=computed tomography; GH=growth hormone; GHRH=growth 
hormone-releasing hormone; IGF-1=insulin-like growth factor 1; MRI=magnetic resonance imaging; SRL=somatostatin 
receptor ligand. © 2006, The New England Journal of Medicine, reproduced with permission. Melmed S et al. (2006).  
N Engl J Med. 355:2558-2573.15
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or when the dose is altered.20 Additionally, 
complications from somatostatin analog therapy 
include hypothyroidism due to the suppression 
of thyroid-stimulating hormone secretion 
and cardiac function abnormalities, such as 
bradycardia, arrhythmias, and conduction 
abnormalities.
Rationale for Dose Optimization in Patients 
with Acromegaly
Control of both GH and IGF-1 can lead to both 
a reversal of co-morbidities and a reduction in 
the risk of premature mortality.16,17,32 In patients 
with acromegaly, the approved starting dose for 
somatostatin analog therapy was determined 
in pharmacokinetic and pharmacodynamic 
studies.31,33 Subsequent studies have shown 
that not all patients at the starting dose report 
a complete normalization of GH and IGF-1 and 
symptom control may vary greatly from one 
patient to another.34-36 Consensus guidelines 
recognized this and reacted by updating the 
treatment guidelines to recommend adjusting 
the somatostatin analog dose in patients who 
do not respond to initial treatment up to the 
highest approved dose and, in some cases, to 
a maximum of 60 mg/month for octreotide 
LAR and 120 mg/month for lanreotide.11,37,38
Alternatively, patients who respond to 
treatment and attain biochemical control at the 
starting dose of octreotide LAR may have their 
dose decreased. 
The following clinical reports present the 
safety and tolerability results specifically 
from studies of dose-optimized treatment 
with somatostatin analogs in patients with 
acromegaly (Table 1).39-44 A study was performed 
in which 125 patients with acromegaly who 
had previously received lanreotide slow 
release (SR) therapy (30 mg/10-14 days) and 
had either undergone previous pituitary 
surgery or received pituitary radiation prior to 
screening were switched to octreotide LAR and, 
if necessary based on response, were given a 
dose adjustment 3 months after switching 
medications.39 The results demonstrate that 
dose titration of octreotide LAR from 20 to 
30 mg/month led to a statistically significant 
decrease in average GH levels among the 
participants; however, among patients treated 
with octreotide LAR (30 mg/month), the 
number of patients with normalized IGF-1 
levels remained the same. The adverse events 
recorded throughout the study demonstrated 
that neither the switch in somatostatin 
analog treatment nor the dose optimization 
of octreotide LAR caused a significant change 
in the safety and tolerability results.39
A lengthy study of octreotide LAR treatment 
(up to 54 months) in 110 patients in which 
59 patients had received previous treatment 
(pituitary surgery, radiation, or both) and the 
remaining had first-line somatostatin analog 
therapy determined that dose optimization led 
to a progressive increase in the percentage of 
patients who achieved IGF-1 normalization.40
Additionally, there were no significant changes 
in routine biochemistry and no clinically 
meaningful increase in fasting glucose levels. 
Transient gastrointestinal side effects (nausea 
and abdominal bloating) were reported in 
8% of the patients and 18% reported new 
biliary abnormalities (gallstones or sludge); 
however, these results were not attributed 
to a particular octreotide LAR dose and are 
similar to the expected occurrence following 
the initial starting dose. A study evaluating 
octreotide LAR doses of up to 40 mg/month 
for a duration of 40 months in patients with 
persistent acromegaly despite prior surgery 
or radiotherapy reported that dose-optimized 
treatment with octreotide LAR improved the 
number of patients who achieved biochemical 
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control.41 Despite the high dose of octreotide 
LAR, the incidence of side effects in all 
patients was low and patient compliance was 
high. Gallstones were detected in 12 patients 
and six patients underwent laparoscopic 
cholecystectomy. The efficacy of lanreotide 
depot in decreasing GH and IGF-1 levels was 
similar to patients treated with octreotide LAR, 
with the most frequent adverse events being 
generally mild or moderate and commonly 
affecting the gastrointestinal system. In 
addition, glucose levels were not statistically 
different between studies of octreotide LAR 
or lanreotide depot, nor did insulin resistance 
change between treatment with the two 
somatostatin analogs.42 A 48-week dose-titration 
study of lanreotide depot was completed by 
59 of 63 patients with acromegaly who 
had received previous somatostatin analog 
therapy (excluding lanreotide depot), surgery, 
or radiotherapy determined that dose 
optimization resulted in normalization of IGF-1 
in 43% of patients and GH levels ≤1 μg/L were 
achieved in 45% of the patients enrolled in the 
study.43 The majority of adverse events in this 
study were mild or moderate in severity, with 
57% of patients reporting at least one episode 
of diarrhea and 27% of patients reporting 
abdominal pain.43 A multicenter study of 
26 patients who did not achieve biochemical 
control (mean baseline GH ≥2 μg/L and IGF-1 
levels above normal) at the conventional dose 
(20 mg/month) of octreotide LAR were treated 
with either high-dose (60 mg/month) or high-
frequency (30 mg every 3 weeks) octreotide 
LAR to achieve control of GH (<2 μg/L) and 
normalization of IGF-1.44 Overall, high-dose 
treatment with octreotide LAR controlled 
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IGF-1 and GH levels in 36% and 20%, 
respectively, of patients who were not able to 
achieve satisfactory biochemical control with 
conventional somatostatin analog therapy. 
Fourteen patients experienced an adverse 
event that was mild to moderate in nature and 
mainly gastrointestinal; however, these were 
not determined to be a dose-response effect.
NET
NET are a diverse group of solid tumors 
that develop as neoplasms from secretory, 
neuroendocrine cells throughout the body 
and comprise about 2% of all malignant 
tumors.45 Historically, NET were regarded as 
rare tumors; however, this thinking may have 
been the result of poor awareness and a lack 
of specific diagnostic techniques. A recent 
review of the US Surveillance Epidemiology 
and End Results (SEER) database by Yao et al.46
suggests that the incidence of NET has been 
steadily increasing, rising from 1.09 new 
cases/100,000 people in the 1970s to 5.25 new 
cases/100,000 people (age-adjusted US 2000 
standard population) in 2004. The increase is 
likely caused by improvements in recognition 
and classification of this tumor class.46 From a 
diagnostic point of view, identification of NET 
is a challenge to most physicians because their 
clinical presentation is subtle and detection 
may occur secondary to routine colonoscopy, 
endoscopic procedure, or as part of an autopsy.47
Previously, NET were divided into three subtypes 
(foregut, midgut, and hindgut) based on their 
embryologic origin (Table 2A);48,49 however, 
recently the practice has changed to classify the 
tumors based on the location of primary origin, 
differentiation/tumor-node-metastasis (TNM) 
grade, and stage (Table 2B).50,51 In addition, 
NET are usually characterized as clinically 
symptomatic (functioning) or silent (non-
functioning) tumors, depending on whether the 
peptides that are secreted produce symptoms. 
Functioning NET are further classified by the 
peptides that are secreted into the system 
Table 2A. Traditional classification of neuroendocrine tumor by embryological origin.
Classification Location
Foregut Thymus, esophagus, lung, stomach, pancreas
Midgut Appendix, ileum, jejunum, cecum, ascending colon
Hindgut Distal large bowel, rectum
Table 2B. Current classification of neuroendocrine tumors based on World Health Organisation (WHO) and tumor-node-
metastases (TNM) guidelines.
Classification Description
Tumor site Primary tumor location (lung, colon, rectal, etc)
Functionality Characteristic clinical symptoms
WHO Biology of the tumor, differentiation, and size 
TNM Stage (location, size, nodes, and metastasis) 
Grade (mitotic count and Ki-67 indexing)
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(eg, serotonin and tachykinins), which can lead 
to subsequent clinical symptoms in the patient; 
the most common being carcinoid syndrome. 
These secondary clinical symptoms may 
increase morbidity and their adverse events 
typically can further complicate effective 
treatment of the patient. Although earlier 
literature considered about a third of NET to be 
non-functioning, recent estimates suggest that 
up to 60% of NET are non-functioning.52 Non-
functioning NET are more difficult to detect 
and may only be found after non-specific local 
effects, such as abdominal symptoms, bowel 
obstruction, and jaundice due to bile-duct 
obstruction, arise as a result of tumor growth 
and metastasis.52,53
Management of NET
Treatment of NET is based on the current stage 
of the disease, with the primary aim being 
to prevent tumor progression and reduce 
the symptoms caused by the secretion of 
bioactive agents. Treatment is individualized 
based on the size and location of the tumor 
and the co-morbidities experienced by the 
patient. The first-line therapy of choice is 
surgery and the effectiveness of removing 
the primary tumor is high if the tumor 
has not metastasized. Otherwise, surgical 
debulking of the tumor is common to reduce 
the symptoms caused by the secondary 
clinical syndromes; however, removal of the 
majority of the tumor volume, including 
the primary tumor if known, is necessary to 
achieve relief of symptoms.1,49 For unresectable 
tumors, the National Comprehensive Cancer 
Network (NCCN) recommends the following 
treatment options: local ablative therapy 
(ie, radiofrequency ablation), regional 
therapy (ie, arterial or chemoembolization), 
cytoreductive surgery, or systemic therapy 
with cytotoxic agents. Most patients with NET 
are not responsive to traditional chemotherapy 
regimens, and cytotoxic agents have not 
demonstrated an overall survival benefit.10
Therefore, medical therapy with somatostatin 
analogs is a viable option either before 
or following surgery to provide symptom 
alleviation, slow tumor progression, and 
improve the patient’s quality of life.54 Similar 
to acromegaly treatment guidelines, the 
NCCN guidelines have confirmed the benefit 
of dose optimization and recommend that the 
patient’s clinical response be evaluated relative 
to the treatment goals and the need for either 
increased doses of the somatostatin analog 
for breakthrough symptoms or ongoing dose 
adjustments to achieve treatment success.49,55
Controlling Symptoms of NET with 
Somatostatin Analogs 
Carcinoid syndrome is the most common 
syndrome associated with NET and is 
characterized by symptoms such as flushing, 
diarrhea, abdominal pain, and right-sided heart 
failure (Figure 3). Greater than 80% of NET 
express sst256 and it is believed the high binding 
affinities and subsequent activation of this sst 
by the somatostatin analogs octreotide LAR 
and lanreotide depot result in the inhibition of 
hormone secretion as well as the possibility of 
an antiproliferative effect on the tumor itself.6,57 
Pooled data from more than 14 trials spanning 
the past two decades revealed that >70% of 
patients with NET treated with octreotide 
LAR experienced symptomatic resolution or 
improvement of diarrhea (40%-88%) and 
flushing (48%-100%).1 However, objective 
tumor responses were shown in only three of 
these trials, with the individual response rates 
ranging between 3% and 9%. The therapeutic 
effects of lanreotide have been studied in 
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11 trials totaling about 300 patients over the 
past decade. The symptomatic improvement 
in diarrhea and flushing (36%-100% and 38%-
100%, respectively) was similar to that with 
octreotide, as was the objective tumor response 
(0%-9%).1 Recently, the antiproliferative effect 
of medical therapy was confirmed in a study 
comparing the control of tumor growth by 
octreotide LAR (30 mg/28 days) versus placebo 
in patients with metastatic NET of the midgut 
(Placebo-controlled prospective Randomized 
study on the antiproliferative efficacy of 
Octreotide LAR in patients with metastatic 
neuroendocrine MIDgut tumors [PROMID] 
study). Treatment with octreotide LAR led 
to a significant increase in time to tumor 
progression (14.3 vs. 6.0 months; P=0.0008).58
As a whole, these studies have demonstrated 
the efficacy of somatostatin analog therapy 
for controlling the symptoms associated with 
NET and slowing tumor progression, but draw 
attention to the need for dose optimization 
to improve symptom control in a greater 
percentage of patients. 
Safety and Tolerability of Dose Optimization 
in Patients with NET
Conventional somatostatin analog doses are 
extremely well tolerated by patients with NET 
and are rarely the cause for discontinuation 
of therapy. The safety of octreotide LAR 
(20 mg) in the treatment of NET was initially 
evaluated in one phase 3 study of 93 patients 
with carcinoid syndrome.59 The adverse events 
experienced by >15% of patients treated with 
octreotide LAR included headache, nausea, and 
dizziness. Additionally, patients experienced 
generalized pain, arthropathy, rash, and 
fatigue. Routine biochemical and hematological 
markers should be monitored in patients treated 
with somatostatin analogs and do not change 
significantly due to treatment; however, patients 
with diabetes mellitus should be monitored 
carefully for co-morbid conditions. Treatment 
with depot formulations of somatostatin 
analogs, such as octreotide LAR and lanreotide 
depot, pose a risk of cholelithiasis and biliary 
tract changes, including gallstones, sediment, 
Figure 3. Carcinoid syndrome and clinical complications of neuroendocrine tumors.
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and sludge. The efficacy of somatostatin analogs, 
such as octreotide and lanreotide, was described 
in a dose-titration study, which determined 
that octreotide subcutaneous doses >500 μg 
(500-2000 μg) three times daily resulted in 
improved carcinoid syndrome control and 
exhibited a greater response rate, defined as 
a 50% reduction in tumor diameter, in 31% 
of patients compared to historical controls 
(20%). This early study of “high-dose therapy” 
also established the safety and tolerability 
of dose optimization in patients with 
NET who experience unresponsive or 
breakthrough symptoms.59
A review of the recent literature shows that 
patients treated with a range of somatostatin 
analog doses do not experience any difference 
in common adverse events when compared 
to initial dosing (Table 3).60-62 A 6-month trial 
of 71 patients with carcinoid syndrome that 
was not controlled by previous somatostatin 
analog therapy or surgery measured the 
efficacy and safety of lanreotide depot dose 
titration based on symptom response.60 The 
study determined that dose optimization 
caused flushing and diarrhea episodes to 
decrease significantly from baseline by a mean 
of 1.3 and 1.1 episodes/day, respectively (both 
P=0.001). In total, 37% of patients reported 
adverse events attributed to treatment with 
lanreotide depot. The most frequent side 
effects were abdominal pain (38%), diarrhea 
(17%), fatigue (15%), vomiting (13%), 
asthenia (11%), nausea (10%), cholelithiasis 
Table 3. Efficacy and tolerability of dose optimization in patients with neuroendocrine tumors. 
Reference SSA dose
Number of 
patients on SSA 
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octreotide LAR up to 
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well tolerated
LAR=long-acting repeatable; SR=slow release; SSA=somatostatin analog.
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is generally effective with reported side effects 
being mild to moderate. When compared to 
the initial somatostatin analog dose, dose 
increase did not cause noteworthy differences 
in adverse events or tolerability; however, 
titration did provide a beneficial improvement 
in efficacy. Additionally, in studies of high-dose 
treatment with octreotide LAR (>40 mg/month) 
or lanreotide (>120 mg/month), there was not 
a considerable rise in reported adverse events. 
From a clinical perspective, dose optimization 
is most commonly used to treat breakthrough 
symptoms that become more persistent and 
frequent in the time period immediately prior 
to the next monthly dose. As clinicians, we 
utilize the consensus guidelines discussed 
in this document as the suitable framework 
to follow when titrating the patient’s dose. 
The safety and tolerability of high-dose treatment 
with somatostatin analogs has been established 
in these treatment guidelines and the studies 
reviewed show an added efficacy benefit without 
increased safety concerns. 
ACKNOWLEDGMENTS 
W.H.L. has received research support from 
Novartis Pharmaceuticals Corporation and 
Indevus Pharmaceuticals and has served as 
a consultant for Pfizer, Indevus, Ipsen, and 
Novartis. L.A. has received research support 
from Pfizer, Novartis, and ImClone and has 
served as consultant for Pfizer, Novartis, 
Molecular Insight Pharmaceuticals, and Roche. 
The authors did not receive any financial 
support for the conceptualization, writing, or 
submission of this manuscript. The authors 
thank Timothy Remus, PhD, for providing 
editorial assistance in the preparation of this 
manuscript. Financial support for editorial 
assistance was provided directly to Mudskipper 
Inc. by Novartis Pharmaceutical Corporation.
(10%), and anorexia (10%).60 A trial designed 
to compare two dose levels of octreotide LAR 
(30 and 40 mg/month) highlighted the ability 
of octreotide LAR to control diarrhea in patients 
with active or prior chemotherapy-induced 
diarrhea.61 Fewer patients in the 40 mg/month 
group compared with those in the 30 mg/
month group experienced severe diarrhea 
(62% vs. 48%; P=0.14), required intravenous 
fluid (32% vs. 19%; P=0.10), or had diarrhea-
related unscheduled healthcare visits (42% vs. 
28%; P=0.11). No significant differences were 
observed between the treatment groups in either 
measured quality of life or treatment satisfaction. 
Most importantly, adverse events were balanced 
between the two groups.61 Finally, a retrospective 
analysis studied the efficacy and tolerability of 
higher doses (>30 mg/month) of octreotide LAR 
in 54 patients with pancreatic NET.62 Patients 
were subdivided into two groups for analysis: 
those who received only the conventional dose 
of octreotide LAR (n=24), and those who started 
with the conventional dose but required dose 
escalation (n=34). No treatment-related toxicities 
were seen in either group, with octreotide LAR 
being well tolerated at higher doses. Relief 
from diarrhea and flushing, reduction in tumor 
volume, and improvements in quality of life 
in patients with NET can be achieved by dose 
optimization of somatostatin analog therapy 
without a significant change in safety and 
tolerability.62
DISCUSSION 
Dose optimization with somatostatin analogs 
has been shown to be an effective means to 
improve treatment outcomes in patients with 
either acromegaly or NET who have inadequate 
response to the starting dose or fail to achieve 
complete control of their disease. Octreotide 
LAR, the most widely used somatostatin analog, 
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